

a²
12

10

~~33. The method of claim 31, wherein the blood disorder is hemophilia.~~

c

13

8

~~34. The method of claim 29 wherein said protein is secreted.~~

gene encodes a secreted protein

REMARKS

Applicants have amended the specification to include a claim for priority and to reflect the continuing information with respect to this application.

Claims 1-22 have been canceled without prejudice and disclaimer.

Applicant expressly reserves the right to bring the claims again in a subsequent, related application.

New claims 23-34 have been added and are directed to methods of administering recombinant adeno-associated virus (AAV) virions into the bloodstream of a mammalian subject (claims 23-28); and methods for expressing a therapeutically effective amount of a protein in a mammalian subject (claims 29-34). Support for the new claims may be found throughout the specification, particularly at page 10, lines 29-34; page 16, lines 8-18; page 20, lines 33-34; page 30, line 33; page 40, lines 13-15; and page 44, lines 20-33.

Accordingly, no new matter has been added by way of the new claims, and the entry thereof is respectfully requested.

Respectfully submitted,

Date: 1/4/01

By: Roberta L. Robins

Roberta L. Robins
Registration No. 33,208

Customer No. 20855
ROBINS & ASSOCIATES
90 Middlefield Road, Suite 200
Menlo Park, CA 94025
Telephone: (650) 325-7812
Fax: (650) 325-7823